ARNA
Get informed when a big investor buys or sells
+ FollowUndervalued by 4.1% based on the discounted cash flow analysis.
| Market cap | $0.00 |
|---|---|
| Enterprise Value | $-509,258,000.00 |
| Dividend Yield | $- (-) |
| Earnings per Share | $-11.33 |
| Beta | 0.55 |
| Outstanding Shares | 61,378,000 |
| P/E Ratio | -8.82 |
|---|---|
| PEG | -32.23 |
| Price to Sales | - |
| Price to Book Ratio | 10.0 |
| Enterprise Value to Revenue | -9430.7 |
| Enterprise Value to EBIT | 0.92 |
| Enterprise Value to Net Income | 0 |
| Total Debt to Enterprise | -0.08 |
| Debt to Equity | 0.06 |
No data
No data available for the latest quarter.
No data available for the latest quarter.
No data
The most powerful economic committee, controlling taxation and entitlement spending (e.g., Medicare/Medicaid). It directly impacts pharmaceutical company profitability through tax policy and influences drug pricing and reimbursement through healthcare legislation.
Directly regulates the FDA, which is responsible for drug approvals, manufacturing standards, and post-market surveillance, making it the primary legislative body for the pharmaceutical sector. It also oversees NIH funding for medical research.
Oversees antitrust laws and intellectual property (patents), both of which are absolutely critical for the pharmaceutical industry regarding product exclusivity, competition, and mergers and acquisitions.